A Boston Scientific executive said that the company received FDA approval for its Farapoint pulsed field ablation (PFA) ...

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation Pulse Biosciences, Inc. (Nasdaq: PLSE), a company ...

As part of the first-in-human trial, participants received more than 15 times the standard dose of the chemotherapy drug doxorubicin every 21 days for up to one year. “Usually, a patient can only ...

FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology. It ensures the benefits of Robotic Magnetic Navigation can ...

Variant Bio, a genomics-driven AI drug discovery company, today announced the launch of Inference, the world's first agentic genomic drug discovery platform. Built on seven years of development and ...

The US president vowed to ‘end childhood cancer’. But his administration is dismantling the search for a cure and sending families scrambling for treatment ...

ActiveState, a global leader in open source language solutions and secure software supply chain management, today announced the release of its 2026 State of Vulnerability Management and Remediation ...

Stereotaxis plans to launch the MAGiC cardiac ablation catheter in early 2026, CEO and Chair David Fischel tells MassDevice.

An LMU research team led by Professor Olivia M. Merkel, Chair of Drug Delivery at LMU, has developed a new delivery system ...

Stereotaxis CEO David Fischel says the MAGiC catheter was designed "to overcome the natural limitations of manual pull-wire ...

The Farapoint device adds another tool to the company’s pulsed field ablation portfolio that could help increase or sustain ...

The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...